Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15

Chung Ying Huang, Tomasz (Tom) Beer, Celestia S. Higano, Lawrence D. True, Robert Vessella, Paul H. Lange, Mark Garzotto, Peter S. Nelson

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance. Experimental Design: Patients with high-risk localized prostate cancer (tumor-node-metastasis ≥T2b or prostate-specific antigen ≥ 15 ng/mL or Gleason glade ≥ 4+3) were enrolled into a phase II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pretreatment prostate tissue was acquired by needle biopsy and posttreatment tissue was acquired by prostatectomy. Prostate epithelium was captured by microdissection, and transcript levels were quantitated by cDNA microarray hybridization. Gene expression changes associated with chemotherapy were determined by a random variance t test. Several were verified by quantitative reverse transcription PCR. In vitro analyses determining the influence of growth differentiation factor 15 (GDF15) on chemotherapy resistance were done. Results: Gene expression changes after chemotherapy were measured in 31 patients who completed four cycles of neoadjuvant chemotherapy. After excluding genes shown previously to be influenced by the radical prostatectomy procedure, we identified 51 genes with significant transcript level alterations following chemotherapy. This group included several cytokines, including GDF15, chemokine (C-X-Cmotif) ligand 10, and interleukin receptor 1β. Overexpression of GDF15 or exposure of prostate cancer cell lines to exogenous recombinant GDF15 conferred resistance to docetaxel and mitoxantrone. Conclusions: Consistent molecular alterations were identified in prostate cancer cells exposed to docetaxel and mitoxantrone chemotherapy. These alterations include transcripts encoding cytokines known to be regulated through the nuclear factor-κB pathway. Chemotherapy-induced cytokines and growth factors, such as GDF15, contribute to tumor cell therapy resistance and may serve as targets to improve responses.

Original languageEnglish (US)
Pages (from-to)5825-5833
Number of pages9
JournalClinical Cancer Research
Volume13
Issue number19
DOIs
StatePublished - Oct 1 2007

Fingerprint

Growth Differentiation Factor 15
Prostate
docetaxel
Carcinoma
Drug Therapy
Mitoxantrone
Prostatectomy
Prostatic Neoplasms
Cytokines
Interleukin-10 Receptor alpha Subunit
C Chemokines
Gene Expression
Neoplasms
Microdissection
Phase II Clinical Trials
Needle Biopsy
Prostate-Specific Antigen
Cell- and Tissue-Based Therapy
Oligonucleotide Array Sequence Analysis
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy : Identification of a cytoprotective mechanism involving growth differentiation factor 15. / Huang, Chung Ying; Beer, Tomasz (Tom); Higano, Celestia S.; True, Lawrence D.; Vessella, Robert; Lange, Paul H.; Garzotto, Mark; Nelson, Peter S.

In: Clinical Cancer Research, Vol. 13, No. 19, 01.10.2007, p. 5825-5833.

Research output: Contribution to journalArticle

@article{5a69bb284e1d4edf9de14df648b452f0,
title = "Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15",
abstract = "Purpose: To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance. Experimental Design: Patients with high-risk localized prostate cancer (tumor-node-metastasis ≥T2b or prostate-specific antigen ≥ 15 ng/mL or Gleason glade ≥ 4+3) were enrolled into a phase II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pretreatment prostate tissue was acquired by needle biopsy and posttreatment tissue was acquired by prostatectomy. Prostate epithelium was captured by microdissection, and transcript levels were quantitated by cDNA microarray hybridization. Gene expression changes associated with chemotherapy were determined by a random variance t test. Several were verified by quantitative reverse transcription PCR. In vitro analyses determining the influence of growth differentiation factor 15 (GDF15) on chemotherapy resistance were done. Results: Gene expression changes after chemotherapy were measured in 31 patients who completed four cycles of neoadjuvant chemotherapy. After excluding genes shown previously to be influenced by the radical prostatectomy procedure, we identified 51 genes with significant transcript level alterations following chemotherapy. This group included several cytokines, including GDF15, chemokine (C-X-Cmotif) ligand 10, and interleukin receptor 1β. Overexpression of GDF15 or exposure of prostate cancer cell lines to exogenous recombinant GDF15 conferred resistance to docetaxel and mitoxantrone. Conclusions: Consistent molecular alterations were identified in prostate cancer cells exposed to docetaxel and mitoxantrone chemotherapy. These alterations include transcripts encoding cytokines known to be regulated through the nuclear factor-κB pathway. Chemotherapy-induced cytokines and growth factors, such as GDF15, contribute to tumor cell therapy resistance and may serve as targets to improve responses.",
author = "Huang, {Chung Ying} and Beer, {Tomasz (Tom)} and Higano, {Celestia S.} and True, {Lawrence D.} and Robert Vessella and Lange, {Paul H.} and Mark Garzotto and Nelson, {Peter S.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1037",
language = "English (US)",
volume = "13",
pages = "5825--5833",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy

T2 - Identification of a cytoprotective mechanism involving growth differentiation factor 15

AU - Huang, Chung Ying

AU - Beer, Tomasz (Tom)

AU - Higano, Celestia S.

AU - True, Lawrence D.

AU - Vessella, Robert

AU - Lange, Paul H.

AU - Garzotto, Mark

AU - Nelson, Peter S.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance. Experimental Design: Patients with high-risk localized prostate cancer (tumor-node-metastasis ≥T2b or prostate-specific antigen ≥ 15 ng/mL or Gleason glade ≥ 4+3) were enrolled into a phase II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pretreatment prostate tissue was acquired by needle biopsy and posttreatment tissue was acquired by prostatectomy. Prostate epithelium was captured by microdissection, and transcript levels were quantitated by cDNA microarray hybridization. Gene expression changes associated with chemotherapy were determined by a random variance t test. Several were verified by quantitative reverse transcription PCR. In vitro analyses determining the influence of growth differentiation factor 15 (GDF15) on chemotherapy resistance were done. Results: Gene expression changes after chemotherapy were measured in 31 patients who completed four cycles of neoadjuvant chemotherapy. After excluding genes shown previously to be influenced by the radical prostatectomy procedure, we identified 51 genes with significant transcript level alterations following chemotherapy. This group included several cytokines, including GDF15, chemokine (C-X-Cmotif) ligand 10, and interleukin receptor 1β. Overexpression of GDF15 or exposure of prostate cancer cell lines to exogenous recombinant GDF15 conferred resistance to docetaxel and mitoxantrone. Conclusions: Consistent molecular alterations were identified in prostate cancer cells exposed to docetaxel and mitoxantrone chemotherapy. These alterations include transcripts encoding cytokines known to be regulated through the nuclear factor-κB pathway. Chemotherapy-induced cytokines and growth factors, such as GDF15, contribute to tumor cell therapy resistance and may serve as targets to improve responses.

AB - Purpose: To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance. Experimental Design: Patients with high-risk localized prostate cancer (tumor-node-metastasis ≥T2b or prostate-specific antigen ≥ 15 ng/mL or Gleason glade ≥ 4+3) were enrolled into a phase II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pretreatment prostate tissue was acquired by needle biopsy and posttreatment tissue was acquired by prostatectomy. Prostate epithelium was captured by microdissection, and transcript levels were quantitated by cDNA microarray hybridization. Gene expression changes associated with chemotherapy were determined by a random variance t test. Several were verified by quantitative reverse transcription PCR. In vitro analyses determining the influence of growth differentiation factor 15 (GDF15) on chemotherapy resistance were done. Results: Gene expression changes after chemotherapy were measured in 31 patients who completed four cycles of neoadjuvant chemotherapy. After excluding genes shown previously to be influenced by the radical prostatectomy procedure, we identified 51 genes with significant transcript level alterations following chemotherapy. This group included several cytokines, including GDF15, chemokine (C-X-Cmotif) ligand 10, and interleukin receptor 1β. Overexpression of GDF15 or exposure of prostate cancer cell lines to exogenous recombinant GDF15 conferred resistance to docetaxel and mitoxantrone. Conclusions: Consistent molecular alterations were identified in prostate cancer cells exposed to docetaxel and mitoxantrone chemotherapy. These alterations include transcripts encoding cytokines known to be regulated through the nuclear factor-κB pathway. Chemotherapy-induced cytokines and growth factors, such as GDF15, contribute to tumor cell therapy resistance and may serve as targets to improve responses.

UR - http://www.scopus.com/inward/record.url?scp=35348827924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348827924&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1037

DO - 10.1158/1078-0432.CCR-07-1037

M3 - Article

C2 - 17908975

AN - SCOPUS:35348827924

VL - 13

SP - 5825

EP - 5833

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -